Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Hypoactive Sexual Desire Disorder - Overview
Female Hypoactive Sexual Desire Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development
Dare Bioscience Inc
Emotiol Brain BV
Endoceutics Inc
Kuhnil Pharmaceutical Co Ltd
Ovoca Bio Plc
Palatin Technologies Inc
S1 Biopharma Inc
Female Hypoactive Sexual Desire Disorder - Drug Profiles
(buspirone hydrochloride + testosterone) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(sildefil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
History of Events
bremelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
KI-1120 - Drug Profile
Product Description
Mechanism Of Action
KI-1128 - Drug Profile
Product Description
Mechanism Of Action
orenetide - Drug Profile
Product Description
Mechanism Of Action
History of Events
prasterone - Drug Profile
Product Description
Mechanism Of Action
History of Events
sildefil citrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
SIP-104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Female Hypoactive Sexual Desire Disorder - Dormant Projects
Female Hypoactive Sexual Desire Disorder - Discontinued Products
Female Hypoactive Sexual Desire Disorder - Product Development Milestones
Featured News & Press Releases
Apr 12, 2022: Freya Pharma Solutions announces appointment of Dr. Jan van der Mooren as chief medical officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD
Feb 22, 2022: Ovoca Bio receives marketing approval for Orenetide for the treatment of hypoactive sexual desire disorder in premenopausal women in Russian Federation
May 04, 2021: Palatin announces U.S. patent term extension for Vyleesi (bremelanotide injection)
Mar 24, 2021: Dar? Bioscience announces initiation of phase 2b RESPOND study of sildefil cream, 3.6% in women with female sexual arousal disorder
Jan 05, 2021: Ovoca Bio announces resubmission of Marketing Authorisation Application with Russian Ministry of Health for BP-101
Oct 02, 2020: Update on Marketing Authorisation application for BP-101 in Russian Federation
Mar 09, 2020: Dare Bioscience presents positive Sildefil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
Dec 11, 2019: Dar? Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildefil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildefil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference
Oct 16, 2019: Vyleesi phase 3 data to be presented at the 13th European Society Of Gynecology Congress
Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101
Aug 27, 2019: AMAG Pharmaceuticals announces commercial availability of Vyleesi (Bremelanotide Injection)
Aug 06, 2019: Palatin Technologies to present data on Vyleesi at Caccord Genuity’s 39th Annual Growth Conference
Jun 21, 2019: AMAG Pharmaceuticals announces FDA approval of Vyleesi (Bremelanotide Injection) for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
Jun 17, 2019: Dar? Bioscience announces positive results in Thermography feasibility study with Sildefil Cream, 3.6%, a potential therapy for female sexual arousal disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Female Hypoactive Sexual Desire Disorder, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Female Hypoactive Sexual Desire Disorder, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Dare Bioscience Inc, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Endoceutics Inc, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Ovoca Bio Plc, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies Inc, 2022
Female Hypoactive Sexual Desire Disorder - Pipeline by S1 Biopharma Inc, 2022
Female Hypoactive Sexual Desire Disorder - Dormant Projects, 2022
Female Hypoactive Sexual Desire Disorder - Discontinued Products, 2022